Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
Alexion replaces CFO Clancy and his 'legendary caution.' Could an M&A spree follow? | Fierce Pharma
Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
Amgen reports pair of positive clinical trial results | Pacific Coast Business Times
Amgen readies case for Soliris copycat as 2025 launch looms
US Biopharma Firm Amgen to Acquire Horizon Therapeutics for $28 Billion | IndustryWeek
Worldwide Orphan Drugs Industry to 2027 - Featuring Alexion Pharmaceuticals, Amgen and Biogen Among Others
Alexion Pharmaceuticals,Inc. Careers and Employment | Indeed.com
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy? | Fierce Pharma
Alexion Pharmaceuticals: Patented Quality at a Great Price | by Shivam Kollur | Medium
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Is Booming Worldwide 2022-2028 | Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc - Digital Journal
Amgen is targeting $BCRX for Acquisition : r/BCRX
Why Amgen Should Buy Alexion Pharmaceuticals | Barron's
Amgen posts positive late-stage data for AstraZeneca's Soliris biosimilar (NASDAQ:AMGN) | Seeking Alpha
Amgen
All 'Alexion Pharmaceuticals' news | Silicon Republic
3 Reasons Why Amgen Could Actually Acquire Alexion
Amgen-Alexion deal rumors resurface, to the delight of investors and analysts | Fierce Pharma
Alexion Is Undervalued And Ripe For Acquisition | The Healthcare Technology Report.
Alexion Pharmaceuticals: In The News And Moving Higher (NASDAQ:ALXN) | Seeking Alpha
